JPRN-jRCT2031220432招募中3 期
Phase 3 Study to Evaluate the Efficacy and Safety of Orally Administered BF2.649 in Japanese Patients with Narcolepsy, Consisting of a Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study (Part 1) and Subsequent Open-label Extension Study (Part 2)
chimura Naohisa0 个研究点目标入组 123 人开始时间: 2022年11月4日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 123
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 15age old 至 < 65age old（—）
- 性别
- All
入选标准
- •Japanese males and females aged 15 or older and less than 65
- •- Individuals who have been diagnosed with narcolepsy (type 1 or type 2)
- •- ESS score is at least 14
排除标准
- •Apnea hypopnea index (AHI) is 15 or above, or Periodic limb movement arousal index (PLMAI) is 10 or above.
研究者
相似试验
尚未招募
3 期
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-Interferon Alfa-2a With Ribavirin in Interferon (IFN) Naive Patients Geno2/3Chronic Hepatits COral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12607000092493Human Genome Sciences, Inc920
进行中（未招募）
1 期
Study to evaluate the efficacy and safety of MarzAA for the control of bleeding episodes in subjects with Haemophilia A or Haemophilia B, with InhibitorsEUCTR2020-000996-19-BGCatalyst Biosciences, Inc.60
进行中（未招募）
1 期
Study to evaluate the efficacy and safety of MarzAA for the control of bleeding episodes in subjects with Haemophilia A or Haemophilia B, with InhibitorsEUCTR2020-000996-19-HUCatalyst Biosciences, Inc.60
进行中（未招募）
1 期
Study to evaluate the efficacy and safety of MarzAA for the control of bleeding episodes in subjects with Haemophilia A or Haemophilia B, with InhibitorsMarzeptacog alfa (activated) (MarzAA), a novel activated recombinant Factor VII (rFVIIa) variant, is being developed by Catalyst Biosciences to address the unmet need in haemophilia and other bleeding disorders.MedDRA version: 20.0Level: LLTClassification code 10066439Term: HemophiliaSystem Organ Class: 100000004850EUCTR2020-000996-19-DKCatalyst Biosciences, Inc.60
招募中
3 期
Phase 3 Study to Evaluate the Efficacy and Safety of Orally Administered BF2.649 in Japanese Patients with Obstructive Sleep Apnea Syndrome Complaining Excessive Daytime Sleepiness despite Treated by Nasal Continuous Positive Airway Pressure (nCPAP), Consisting of a Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study (Part 1) and Subsequent Open-label Extension Study (Part 2)obstructive sleep apnea syndromeJPRN-jRCT2031220501chimura Naohisa148